UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

The Lancet (British edition), 2015-09, Vol.386 (9999), p.1156-1164

2015

Volltextzugriff (PDF)

Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women

Revista Brasileira de ginecologia e obstetrícia, 2015-06, Vol.37 (6), p.258-265

2015

Volltextzugriff (PDF)

Liability cases: complications in 2 cases with intravenous infusions. Death caused by high dosage of actinomycin

Tidskrift for Sveriges sjukskoterskor, 1971-03, Vol.38 (6), p.16

1971

Volltextzugriff (PDF)

Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

The lancet oncology, 2018-08, Vol.19 (8), p.1061-1071

2018

Volltextzugriff (PDF)

First line chemotherapy in low risk gestational trophoblastic neoplasia

Cochrane database of systematic reviews, 2009-01 (1), p.CD007102

2009

Volltextzugriff (PDF)

First-line chemotherapy in low-risk gestational trophoblastic neoplasia

Cochrane database of systematic reviews, 2016-06, Vol.2019 (6), p.CD007102

2016

Volltextzugriff (PDF)

Increased local failure for patients with intermediate‐risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group

Cancer, 2019-09, Vol.125 (18), p.3242-3248

2019

Volltextzugriff (PDF)

EMA/CO for High-Risk Gestational Trophoblastic Neoplasia: Good Outcomes With Induction Low-Dose Etoposide-Cisplatin and Genetic Analysis

Journal of clinical oncology, 2013-01, Vol.31 (2), p.280-286

2013

Volltextzugriff (PDF)

Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial

Journal of clinical oncology, 2014-08, Vol.32 (23), p.2440-2448

2014

Volltextzugriff (PDF)

Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Journal of clinical oncology, 2014-11, Vol.32 (31), p.3547-3552

2014

Volltextzugriff (PDF)

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5182-5188

2009

Volltextzugriff (PDF)

High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas

Genes chromosomes & cancer, 2012-03, Vol.51 (3), p.207-218

2012

Volltextzugriff (PDF)

Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532

Journal of clinical oncology, 2018-01, Vol.36 (3), p.254-261

2018

Volltextzugriff (PDF)

Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2536-2541

2009

Volltextzugriff (PDF)

Reduction of cyclophosphamide dose for patients with subset 2 low‐risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Cancer, 2017-06, Vol.123 (12), p.2368-2375

2017

Volltextzugriff (PDF)

Randomized Comparison of Intensified Six-Drug Versus Standard Three-Drug Chemotherapy for High-Risk Nonmetastatic Rhabdomyosarcoma and Other Chemotherapy-Sensitive Childhood Soft Tissue Sarcomas: Long-Term Results From the International Society of Pediatric Oncology MMT95 Study

Journal of clinical oncology, 2012-07, Vol.30 (20), p.2457-2465

2012

Volltextzugriff (PDF)

Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade

Cancer immunology research, 2018-02, Vol.6 (2), p.189-200

2018

Volltextzugriff (PDF)

An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275

Gynecologic oncology, 2020-08, Vol.158 (2), p.354-360

2020

Volltextzugriff (PDF)

International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol

Trials, 2020-01, Vol.21 (1), p.96-9, Article 96

2020

Volltextzugriff (PDF)

Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause

Journal of clinical oncology, 2015-02, Vol.33 (5), p.472-478

2015

Volltextzugriff (PDF)

EMA vs EMACO in the treatment of gestational trophoblastic neoplasia

Gynecologic oncology, 2020-07, Vol.158 (1), p.99-104

2020

Volltextzugriff (PDF)

Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience

European journal of cancer (1990), 2016-04, Vol.57, p.1-9

2016

Volltextzugriff (PDF)

Combination chemotherapy for high-risk gestational trophoblastic tumour

Cochrane database of systematic reviews, 2009-01 (2), p.CD005196

2009

Volltextzugriff (PDF)

Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis

Proceedings of the National Academy of Sciences - PNAS, 2016-09, Vol.113 (38), p.10666-10671

2016

Volltextzugriff (PDF)

1 – 25 von 2.035

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.607)
Mit Volltextzugriff
(1.257)

Publikationsform

Artikel
(2.033)
magazinearticle
(2)

Sprache

13 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Dactinomycin - Administration & Dosage
(1.684)
Humans
(1.636)
Science & Technology
(1.309)
Life Sciences & Biomedicine
(1.296)
Female
(1.144)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(1.044)
Male
(946)
Vincristine - Administration & Dosage
(946)
Cyclophosphamide - Administration & Dosage
(855)
Oncology
(709)
Adult
(678)
Biological And Medical Sciences
(562)
Medical Sciences
(527)
Doxorubicin - Administration & Dosage
(495)
Combined Modality Therapy
(479)
Adolescent
(472)
Child
(465)
Animals
(446)
Methotrexate - Administration & Dosage
(434)
Child, Preschool
(389)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women

Liability cases: complications in 2 cases with intravenous infusions. Death caused by high dosage of actinomycin

Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

First line chemotherapy in low risk gestational trophoblastic neoplasia

First-line chemotherapy in low-risk gestational trophoblastic neoplasia

Increased local failure for patients with intermediate‐risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group

EMA/CO for High-Risk Gestational Trophoblastic Neoplasia: Good Outcomes With Induction Low-Dose Etoposide-Cisplatin and Genetic Analysis

Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial

Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas

Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532

Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study

Reduction of cyclophosphamide dose for patients with subset 2 low‐risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Randomized Comparison of Intensified Six-Drug Versus Standard Three-Drug Chemotherapy for High-Risk Nonmetastatic Rhabdomyosarcoma and Other Chemotherapy-Sensitive Childhood Soft Tissue Sarcomas: Long-Term Results From the International Society of Pediatric Oncology MMT95 Study

Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade

An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275

International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol

Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause

EMA vs EMACO in the treatment of gestational trophoblastic neoplasia

Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience

Combination chemotherapy for high-risk gestational trophoblastic tumour

Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis

Suchergebnisse filtern